PP071. suPAR levels in normal- and preeclamptic pregnancies

Area of Science:

• Reproductive Medicine
• Immunology
• Biomarker Discovery

Background:

• Preeclampsia (PE) is a pregnancy complication linked to maternal inflammation.
• Soluble urokinase Plasminogen Activator receptor (suPAR) indicates systemic inflammation and immune activation.

Purpose of the Study:

• To investigate suPAR levels in normal and preeclamptic pregnancies during the first and third trimesters.
• To assess suPAR as a potential biomarker for PE detection.

Main Methods:

• Two studies analyzed serum suPAR levels using ELISA.
• First trimester samples: 43 PE-developing women vs. 86 controls.
• Third trimester samples: 13 PE cases vs. 8 controls.

Main Results:

• No significant difference in first trimester suPAR between groups.
• Third trimester suPAR levels were significantly higher in the PE group (p=0.008).
• This difference was not statistically significant after adjusting for gestational age (p=0.064).

Conclusions:

• suPAR is not a suitable marker for detecting established PE or as a pre-clinical indicator.
• Observed higher suPAR in the first trimester compared to the third suggests a potential physiological role requiring further research.